## DGX: Quest Diagnostics Incorporated - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -4.8% below STRENGTH zone (3.0-6.0%); PEG 1.47 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($175.23)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Quest Diagnostics, Octave Collaborate to Expand Multiple Sclerosis Disease Activity Test Access**
- Source: MarketScreener | 20251201T153300 | Somewhat-Bullish | Relevance: 99%
- Quest Diagnostics and Octave Bioscience have announced a collaboration to broaden access to Octave's Multiple Sclerosis Disease Activity Test across the United States. This partnership aims to make advanced diagnostic testing more widely available for individuals with multiple sclerosis.

**2. First National Advisers LLC Purchases Shares of 8,980 Quest Diagnostics Incorporated $DGX**
- Source: MarketBeat | 20251202T050820 | Somewhat-Bullish | Relevance: 99%
-  First National Advisers LLC initiated a new position in Quest Diagnostics (NYSE:DGX) during Q2, acquiring 8,980 shares valued at approximately $1.61 million. This comes amid significant insider selling from CEO J.E. Davis and SVP Mark E. Delaney, totaling over 94,000 shares. Quest Diagnostics reported strong Q3 earnings, beating estimates with $2.60 EPS and $2.82 billion in revenue, and declared a quarterly dividend of $0.80.

**3. Russell Investments Group Ltd. Acquires 25,768 Shares of Quest Diagnostics Incorporated $DGX**
- Source: MarketBeat | 20251202T180729 | Bullish | Relevance: 99%
-  Russell Investments Group Ltd. increased its stake in Quest Diagnostics Incorporated (NYSE:DGX) by 40.8%, purchasing an additional 25,768 shares to reach a total of 88,848 shares valued at approximately $15.94 million. The medical research company reported strong Q2 earnings, beating analyst expectations with $2.60 EPS and $2.82 billion in revenue, and announced a quarterly dividend of $0.80 per share. Institutional investors own 88.06% of the stock, while analysts maintain a "Moderate Buy" consensus rating with a target price of $196.31.

**4. Quest Diagnostics (NYSE: DGX) to offer Octave MSDA MS blood test at 7,000 U.S. sites**
- Source: Stock Titan | 20251201T083000 | Bullish | Relevance: 99%
- Octave Bioscience has announced a strategic collaboration with Quest Diagnostics to expand access to the OctaveÂ® Multiple Sclerosis Disease Activity (MSDA) Test across the United States. This partnership will allow patients to access the blood test at approximately 7,000 Quest Diagnostics patient access sites nationwide, making it easier for physicians to order and utilize for informed treatment decisions for MS patients. The collaboration also establishes a pathway for future novel tests from Octave's precision neurology portfolio.

**5. 1,325,624 Shares in Quest Diagnostics Incorporated $DGX Purchased by Norges Bank**
- Source: MarketBeat | 20251203T150859 | Somewhat-Bullish | Relevance: 98%
-  Norges Bank recently acquired a new position of 1,325,624 shares in Quest Diagnostics (NYSE:DGX), valued at approximately $238.1 million, representing about 1.19% ownership. This comes as Quest Diagnostics exceeded quarterly earnings estimates and provided a positive FY2025 guidance, contributing to a "Moderate Buy" consensus rating among analysts. Despite some insider selling, institutional investors collectively own 88.06% of the company's stock, reflecting strong confidence in the medical research firm.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 9 ($1.18M) |
| Sells | 8 ($8.86M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.8% (+0.1%)
- Blackrock Inc.: 9.0% (-3.0%)
- JPMORGAN CHASE & CO: 7.8% (+99.3%)
- Price (T.Rowe) Assoc: 6.3% (-2.6%)
- State Street Corpora: 4.7% (+0.8%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-3.2% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $8.9M in recent transactions.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.47 suggests fair value with growth premium. Forward P/E 17.6x stretched relative to 6% growth. Insider selling cluster ($8.9M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.1B |
| Beta | 0.62 |
| 52W Range | $148.70 - $197.55 |
| Short Interest | 4.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.47 |
| Forward P/E | 17.6 |
| Current P/E | 18.6 |
| YoY Growth | 5.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -1.6% to -4.8% (-3.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.8pp (needs >3.0% for momentum thesis). Underperforming sector by 4.5pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.03x) but short-term weakness (below SMA20). MACD histogram bearish (-0.62), momentum weakening. RSI neutral at 45.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -4.77% (CS: 7) | Weak |
| RSI_14 | 44.7 | Neutral |
| MACD Histogram | -0.62 | Bearish |
| vs SMA20 | 0.983x | Below |
| vs SMA50 | 0.992x | Below |
| vs SMA200 | 1.034x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $182.61
- **Stop Loss:** $175.23 (4.0% risk)
- **Target:** $189.99 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 128
- **Position Value:** $23,374.08
- **Portfolio %:** 23.37%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite. VIX at 16 is below median, showing calm, but breadth is only moderate and put/call is neutral, suggesting neither strong bullish nor defensive extremes. Key drivers are rising Fed rate-cut odds from soft ADP jobs data, mixed earnings across sectors, and ongoing AI/tech strength offset by caution in cyclicals and banks. Positioning should remain selective and neutral, awaiting more decisive macro or earnings signals.*

### Earnings

**Next:** 2026-01-27 (Est: $2.36)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.60 | +3.9% |
| 2025Q2 | $2.57 | $2.62 | +1.9% |
| 2025Q1 | $2.15 | $2.21 | +2.8% |
| 2024Q4 | $2.18 | $2.23 | +2.1% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*